← Leaderboards
James B. Doub
University Of Pittsburgh At Pittsburgh
$1,218,837
Attributed
$2,437,673
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $972K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,437,673 · 3
By mechanism
R01$1,608,341 · 1
R21$829,332 · 2
Top collaborators
- Kenneth L Urish5 shared
- Ashley Levack2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Kenneth L Urish$2,016,497
- Ghady Haidar$895,725
- Alexander Sundermann$128,655
Others in their field
Other Rising Stars on “Novel Therapeutics”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Angee Greer · Ppd Development Lp$82,531,927
- Suma Babu · Massachusetts General Hospital$26,348,733
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Cynthia M Visness · Rho Federal Systems Division, Inc.$13,531,908
Research focus
Novel TherapeuticsComplicationTreatment ProtocolsReproducibilityMortalitySeriesIn VivoTissuesMicrobial BiofilmsOperative Surgical ProceduresStaphylococcus AureusProtocols DocumentationSafetyBoneBacteriaImplantAntibioticsPathway InteractionsBacteriophagesPeriprosthetic Joint InfectionPhenotypeFailureChronicKnee Replacement Arthroplasty
Grant awards (7)
Preclinical Research to Determine Prosthetic Joint Infection Pathophysiology Needed to Direct Clinical Bacteriophage Therapy$447,783
R21 · FY2025 · AI
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$359,683
R01 · FY2025 · AR
The utility of bacteriophage therapy in fracture-related infections: Preclinical research needed to create effective and reproducible treatment protocols$164,540
R21 · FY2025 · AR
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$396,697
R01 · FY2024 · AR
The utility of bacteriophage therapy in fracture-related infections: Preclinical research needed to create effective and reproducible treatment protocols$217,009
R21 · FY2024 · AR
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$415,459
R01 · FY2023 · AR
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$436,502
R01 · FY2022 · AR